Short-term curative effect of Buqi Yishen decoction combined with chemotherapy in the treatment of patients with colorectal cancer and its influence on immune function and tumor markers

中国基层医药 Pub Date : 2020-02-15 DOI:10.3760/CMA.J.ISSN.1008-6706.2020.04.019

Guoqun Gu, Yaohua Fan

{"title":"Short-term curative effect of Buqi Yishen decoction combined with chemotherapy in the treatment of patients with colorectal cancer and its influence on immune function and tumor markers","authors":"Guoqun Gu, Yaohua Fan","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.04.019","DOIUrl":null,"url":null,"abstract":"目的 \n探讨补肾益气方联合化疗治疗结直肠癌的近期疗效及对患者免疫功能、肿瘤标志物的影响。 \n \n \n方法 \n选择嘉兴市第二医院2017年1月至2019年1月收治的结直肠癌患者102例为研究对象，采用随机数字表法分为观察组51例与对照组51例。对照组患者予化疗治疗，观察组在对照组基础上联合补气益肾方治疗。两组均以21 d为1个疗程，共3个疗程。比较两组近期疗效，治疗前后卡氏功能状态量表(KPS)评分、免疫功能和肿瘤标志物变化及不良反应发生情况。 \n \n \n结果 \n观察组近期总有效率(76.47%)高于对照组(54.90%)(χ2＝5.263，P<0.05)；观察组治疗后KPS评分[(86.54±5.28)分]高于对照组[(78.98±5.32)分](t＝7.203，P<0.05)。观察组治疗后CD3＋[(63.28±5.64%)]、CD4＋[(39.82±4.21%)]和CD4＋/CD8＋[(1.67±0.23)]均高于对照组[(46.71±4.25%)、(29.34±2.43%)和(0.86±0.14)](t＝16.756、15.397、21.483，均P<0.05)。观察组治疗后癌胚抗原(CEA)[(8.98±1.89)μg/L]和糖类抗原724(CA724)[(7.98±1.74)μg/L]均低于对照组[(15.79±2.54)μg/L和(14.19±2.09)μg/L](t＝15.361、16.308，均P<0.05)。观察组血小板减少(13.73%)、白细胞减少(11.76%)、肝肾异常(7.84%)、胃肠道反应(15.09%)和乏力(13.73%)均低于对照组(35.29%、29.41%、27.45%、49.02%和37.25%)(χ2＝6.411、4.875、6.746、12.946、7.433，均P<0.05)。 \n \n \n结论 \n补气益肾方联合化疗对结直肠癌患者近期疗效明显，可增强机体免疫功能，降低血清CEA和CA724水平，不良反应少。","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":"27 1","pages":"471-474"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.04.019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

目的探讨补肾益气方联合化疗治疗结直肠癌的近期疗效及对患者免疫功能、肿瘤标志物的影响。方法选择嘉兴市第二医院2017年1月至2019年1月收治的结直肠癌患者102例为研究对象，采用随机数字表法分为观察组51例与对照组51例。对照组患者予化疗治疗，观察组在对照组基础上联合补气益肾方治疗。两组均以21 d为1个疗程，共3个疗程。比较两组近期疗效，治疗前后卡氏功能状态量表(KPS)评分、免疫功能和肿瘤标志物变化及不良反应发生情况。结果观察组近期总有效率(76.47%)高于对照组(54.90%)(χ2＝5.263，P<0.05)；观察组治疗后KPS评分[(86.54±5.28)分]高于对照组[(78.98±5.32)分](t＝7.203，P<0.05)。观察组治疗后CD3＋[(63.28±5.64%)]、CD4＋[(39.82±4.21%)]和CD4＋/CD8＋[(1.67±0.23)]均高于对照组[(46.71±4.25%)、(29.34±2.43%)和(0.86±0.14)](t＝16.756、15.397、21.483，均P<0.05)。观察组治疗后癌胚抗原(CEA)[(8.98±1.89)μg/L]和糖类抗原724(CA724)[(7.98±1.74)μg/L]均低于对照组[(15.79±2.54)μg/L和(14.19±2.09)μg/L](t＝15.361、16.308，均P<0.05)。观察组血小板减少(13.73%)、白细胞减少(11.76%)、肝肾异常(7.84%)、胃肠道反应(15.09%)和乏力(13.73%)均低于对照组(35.29%、29.41%、27.45%、49.02%和37.25%)(χ2＝6.411、4.875、6.746、12.946、7.433，均P<0.05)。结论补气益肾方联合化疗对结直肠癌患者近期疗效明显，可增强机体免疫功能，降低血清CEA和CA724水平，不良反应少。

查看原文本刊更多论文

补气益肾汤联合化疗治疗结直肠癌的近期疗效及对免疫功能和肿瘤标志物的影响

Objective: To explore the short-term efficacy of Bushen Yiqi Formula combined with chemotherapy in the treatment of colorectal cancer and its impact on patients' immune function and tumor markers. Method: 102 patients with colorectal cancer admitted to the Second Hospital of Jiaxing City from January 2017 to January 2019 were selected as the study subjects. They were randomly divided into an observation group of 51 cases and a control group of 51 cases using a random number table method. The control group patients were treated with chemotherapy, while the observation group was treated with a combination of tonifying qi and kidney formula on the basis of the control group. Both groups were treated with 21 days as a course of treatment, totaling 3 courses. Compare the recent efficacy of the two groups, including the score of KPS before and after treatment, changes in immune function and tumor markers, and the occurrence of adverse reactions. The recent total effective rate of the observation group (76.47%) was higher than that of the control group (54.90%)（ χ 2=5.263, P<0.05); The KPS score of the observation group after treatment [(86.54 ± 5.28) points] was higher than that of the control group [(78.98 ± 5.32) points] (t=7.203, P<0.05). After treatment, the levels of CD3+[(63.28 ± 5.64%)], CD4+[(39.82 ± 4.21%)], and CD4+/CD8+[(1.67 ± 0.23)] in the observation group were higher than those in the control group [(46.71 ± 4.25%), (29.34 ± 2.43%), and (0.86 ± 0.14)] (t=16.756, 15.397, 21.483, all P<0.05). Posttreatment carcinoembryonic antigen (CEA) in the observation group [(8.98 ± 1.89) μ G/L] and carbohydrate antigen 724 (CA724) [(7.98 ± 1.74) μ G/L] is lower than the control group [(15.79 ± 2.54) μ G/L and (14.19 ± 2.09) μ G/L] (t=15.361, 16.308, all P<0.05). The observation group showed lower levels of thrombocytopenia (13.73%), leukopenia (11.76%), liver and kidney abnormalities (7.84%), gastrointestinal reactions (15.09%), and fatigue (13.73%) compared to the control group (35.29%, 29.41%, 27.45%, 49.02%, and 37.25%)（ χ 2=6.411, 4.875, 6.746, 12.946, 7.433, all P<0.05). Conclusion: The combination of Bu Qi Yi Shen Fang and chemotherapy has a significant short-term therapeutic effect on colorectal cancer patients, which can enhance the body's immune function, reduce serum CEA and CA724 levels, and have fewer adverse reactions.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国基层医药

CiteScore

0.10

自引率

0.00%

发文量

32251

期刊介绍： Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.